We have tested this by employing small molecule VRK1 inhibitors that inhibit the VRK1-mediated BAF phosphorylation and consequently prevent nuclear envelope break down or reassembly in cancer cells, suggesting that inhibition of VRK1 renders cancer cells, which contain underlying nuclear envelope defects, more vulnerable64, 65. This evidence concerns the gene VRK1 and cancer.